Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Ireland
  4. Irish Stock Exchange
  5. Elan Corporation Ltd
  6. News
  7. Summary
    DRX   IE0003072950

ELAN CORPORATION LTD

(DRX)
SummaryChartsNewsCompany 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Elan bid to fend off Royalty handed boost in buyback

04/18/2013 | 11:50am EDT

DUBLIN/NEW YORK (Reuters) - Elan (>> Elan Corporation, plc) shareholders gave the Irish drug maker a boost in its hopes of fending off a $7.3 billion (4.7 billion pounds) bid from Royalty Pharma when they ignored a plea from the U.S. investment firm to tender stock at a high price at a buyback on Thursday.

DUBLIN/NEW YORK (Reuters) - Elan (>> Elan Corporation, plc) shareholders gave the Irish drug maker a boost in its hopes of fending off a $7.3 billion (4.7 billion pounds) bid from Royalty Pharma when they ignored a plea from the U.S. investment firm to tender stock at a high price at a buyback on Thursday.

Royalty, which sweetened its offer for Elan this week, urged shareholders to "send a message to the Elan board" by tendering all of their stock at $11.75 or $12 to fully benefit from its $12 per share offer.

However Elan said only 4 percent of shares were tendered at Royalty's preferred mark and that it bought back the targeted $1 billion of stock at the bottom of the $11.25 to $13 range, with U.S. drug maker Johnson & Johnson (>> Johnson & Johnson) accounting for 92.3 percent of all shares purchased.

The results of the tender offer appear to indicate that Elan shareholders either believe that Elan CEO Kelly Martin can rebuild the company through acquisitions or that Royalty Pharma will come back with a higher bid, analysts said.

"It's a strong message that the shareholder base of Elan is not thinking about tendering at the $13 level," said Adrian Howd, an analyst at Berenberg Bank.

It might also be good news for Elan that Johnson & Johnson (J&J), which never appeared to be a strategic investor in Elan, has reduced its stake in Elan from 18 percent to 4.9 percent and tendered all its shares, Howd said.

J&J, which said it will make a $213 million gain from the sale, paid $1 billion for its holding in 2009 in a deal that gave both drug makers a 25 percent share in bapineuzumab, an experimental Alzheimer's treatment that failed last year.

"It means that the shareholder base is now more supportive in that the sense that you have more shareholders that care about the shares being above $13 a share," Howd said.

The strike price of $11.25, which retires 14.8 percent of the current shares in issue, means that according to details published by Royalty on Monday, its bid is now pushed back to $11.25, including a net cash right worth up to $1.00.

The New York-based company, targeting royalty rights for multiple sclerosis (MS) treatment Tysabri worth hundreds of millions of dollars annually, made the offer ahead of a May 10 deadline to make a firm bid.

Elan, which rejected Royalty's initial offer of $11 per share for being "highly conditional", plans to reinvent itself through a series of acquisitions after selling its 50 percent interest in Tysabri for $3.

The Dublin-based company, left with just one experimental drug in its pipeline following the Tysabri deal, improved the terms of its own plan last month by offering shareholders up to 20 percent of future royalties from the blockbuster MS drug.

But whether Elan's shareholder will be correct on their bet not to tender at $13 a share remains to be seen. Some analysts agree with Royalty's assessment that Elan's management has little track record in making big acquisitions.

"I don't know why shareholders would not sell out at that level," said Nick Turner, an analyst at Mirabaud Securities.

"Whether they believe they can get a better return out of Elan under current management... that is not an argument that holds water with me."

(Additional reporting by Ransdell Pierson; Editing by Clelia Oziel/Mark Heinrich)

By Padraic Halpin and Jessica Toonkel

Stocks treated in this article : Elan Corporation, plc, Johnson & Johnson

© Reuters 2013
Stocks mentioned in the article
ChangeLast1st jan.
BASE CO., LTD. 1.75% 4935 End-of-day quote.-19.76%
BASE, INC. -3.36% 1525 End-of-day quote.-21.88%
ELAN CORPORATION LTD -0.39% 12.71 End-of-day quote.0.00%
JOHNSON & JOHNSON 1.06% 171.79 Delayed Quote.9.16%
ROYALTY PHARMA PLC -0.07% 40.33 Delayed Quote.-19.42%
All news about ELAN CORPORATION LTD
2014With eye on tax rates, Horizon Pharma buys Ireland's Vidara
RE
2013Ex-SAC manager Martoma fails to end part of insider case
RE
2013ELAN CORPORATION, PLC : Perrigo Company and Elan Corporation Plc Receive Irish H..
PU
2013Ex-SAC trader points to Cohen testimony in insider trading case
RE
2013ELAN CORPORATION, PLC : Elan Announces Shareholder Approval of its Acquisition b..
BU
2013Elan wins shareholder approval to complete Perrigo sale
RE
2013The prosecutors with SAC Capital in their crosshairs
RE
2013ELAN CORPORATION, PLC : Elan Reports Third Quarter 2013 Financial Results
BU
2013EXCLUSIVE - TPG-BACKED APTALIS PHARM : sources
RE
2013ELAN CORPORATION, PLC : Elan Announces Webcast of Third Quarter 2013 Financial R..
BU
More news
Chart ELAN CORPORATION LTD
Duration : Period :
Elan Corporation Ltd Technical Analysis Chart | DRX | IE0003072950 | MarketScreener
Sector and Competitors
1st jan.Capi. (M$)
ELAN CORPORATION LTD0.00%0
MODERNA, INC.233.90%88 312
LONZA GROUP AG24.05%53 538
IQVIA HOLDINGS INC.39.02%47 022
CELLTRION, INC.-25.21%32 170
SEAGEN INC.-16.87%28 525